



Otros tumores torácicos

Enric Carcereny


Institut Català d'Oncologia Badalona

Badalona-Applied Research Group in Oncology (B-ARGO)


Otros tumores torácicos

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

Study Design



Overall Survival



- 4-year PFS rates were 9% vs 0% with NIVO + IPI vs chemo^c
- ORR and DOR were consistent with previous database lock^d; rate of ongoing responders at 4 years was 16% vs 0%, respectively

Minimum / median follow-up for OS: 47.5 months / 55.1 months.


Subsequent systemic therapy was received by 46% of patients in the NIVO + IPI arm and 43% in the chemo arm; subsequent immunotherapy was received by 5% and 23%; subsequent chemotherapy was received by 44% and 34%, respectively.

^a95% CIs were 16.8-21.0 (NIVO + IPI) and 12.4-16.3 (chemo); ^b95% CIs were 12.7-21.5 (NIVO + IPI) and 7.5-14.7 (chemo); ^cMedian PFS was 6.8 vs 7.2 months with NIVO + IPI vs chemo (HR, 95% CI: 0.93, 0.77-1.13); ^dORR was 39.3% vs 44.4%, and median DOR was 11.6 vs 6.8 months.

Otros tumores torácicos

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743


Overall Survival by Histology



Otros tumores torácicos

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743


Overall Survival by baseline soluble mesothelin level



Otros tumores torácicos

First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

Overall Survival by MPM specific tumor suppressor gene mutations



Minimum / median follow-up for OS: 47.5 months / 55.1 months.

Otros tumores torácicos

Conclusiones

1. La combinación de Nivolumab + Ipilimumab sigue demostrando beneficio en supervivencia a los 4 años de seguimiento frente a la quimioterapia.
2. El 16% de los respondedores a la inmunoterapia continúan respondiendo a los 4 años frente a ninguno en el brazo de quimioterapia.
3. Los niveles elevados de mesotelina basal se correlacionan con un peor pronóstico, independientemente del brazo de tratamiento.
4. .En el análisis exploratorio de biomarcadores, entre los distintos genes supresores analizados, el beneficio es mayor para el brazo de inmunoterapia.
5. No aparecen nuevos datos seguridad con este mayor seguimiento

